Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 73 | ECE2021 | Next issue

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

Card image cap
The European Congress of Endocrinology provides a global platform for the international endocrine community to discuss the latest advances in the field.

Oral Communications

Oral Communications 8: Pituitary and Neuroendocrinology

ea0073oc8.1 | Oral Communications 8: Pituitary and Neuroendocrinology | ECE2021

Expression and putative role of 14–3-3 proteins in corticotroph tumours

Tang Sicheng , Perez-Rivas Luis Gustavo , Albani Adriana , Rotermund Roman , Flitsch Jörg , Honegger Jürgen , Rachinger Walter , Sigrun Röber , Herms Jochen , Reincke Martin , Theodoropoulou Marily

IntroductionSomatic USP8 mutations are found in around 50% of Cushing’s disease tumours and are located in a single mutational hotspot that contains the recognition site for 14–3-3. These proteins bind to phosphoserine recognition motifs to alter the function and location of their target proteins, and are deregulated in several cancers. AimTo explore the expression and function of 14–3-3 prot...

ea0073oc8.2 | Oral Communications 8: Pituitary and Neuroendocrinology | ECE2021

Osilodrostat is an effective and well-tolerated treatment option for patients with Cushing’s disease (CD): Final results from the LINC3 study

Fleseriu Maria , Biller Beverly , Pivonello Rosario , Akira Shimatsu , Carla Scaroni , Belaya Zhanna , Vila Greisa , Houde Ghislaine , Walia Rama , Izquierdo Miguel , Roughton Michael , Pedroncelli Alberto , Newell-Price John

IntroductionOsilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during the 48-week (W) core phase of a Phase III study (LINC3: NCT02180217). We present efficacy and safety results following an extension to LINC3.MethodsCD patients with mUFC > 1.5× upper limit of normal (ULN) received osilodrostat during the core. Patients b...

ea0073oc8.3 | Oral Communications 8: Pituitary and Neuroendocrinology | ECE2021

GFRα2 as a GPS marker: Role of GFRα2 in pituitary gland

Pradilla Dieste Alberto , García Lavandeira Montserrat , Pérez-Romero Sihara , Graça Fonseca Jesuina Arcángela , Kupari Jussi , Japón Miguel , Airaksinen Matti S. , Álvarez Clara V.

The pituitary gland is the master gland of the endocrine system, controlling important physiological steps like growth, puberty or reproduction. There are different endocrine cell types within the adenopituitary, each one producing a specific hormone. Adaptation to different life stages and moments requires a plastic capacity based in proliferation and differentiation of pituitary stem cells. We ans others discovered the existence of a stem cell niche in the pituitary. Parench...

ea0073oc8.4 | Oral Communications 8: Pituitary and Neuroendocrinology | ECE2021

Novel insight into ACTH-secreting pituitary tumors biological behavior: hormone secretion and cell proliferation modulation by Ubiquitin Specific Peptidase 8 inhibitor RA-9

Di Muro Genesio , Treppiedi Donatella , Marra Giusy , Mangili Federica , Catalano Rosa , Barbieri Anna Maria , Locatelli Marco , Spada Anna , Arosio Maura , Mantovani Giovanna , Peverelli Erika

Cushing’s Disease (CD) is a rare condition mostly caused by an ACTH-secreting pituitary tumor resulting in excess of cortisol release by the adrenal glands. Although pasireotide is the only pituitary-targeted drug approved to treat adult patients, many side effects are encountered during the clinical practice and a curative therapy for CD is still challenging. Recently, the discover of somatic mutations in the deubiquitinase USP8 gene in a subset of patients has ...

ea0073oc8.5 | Oral Communications 8: Pituitary and Neuroendocrinology | ECE2021

The clinical effects of miR-26a, miR-16, let-7, miR-128a and miR-223 in acromegaly patients

Cagrı Bosna Islam , Cinar Nese , Edgunlu Tuba , Akbaba Gulhan , Yaylali Guzin , Sevim Karakas Celik , Ebru Onalan Etem , Celik Aycan , Gizem Bircan Murside

Background and aimMicroRNAs (miRNA) are small nucleotide sequences that affect gene expression in cells at the posttranscriptional level. Some miRNAs behave like oncogenes, while others behave like tumor suppressors. In this study, it was aimed to investigate the role of miRNAs in tumor development and its effects on clinical and metabolic parameters of the patients with acromegaly.Methods39 patients diagnose...

ea0073oc8.6 | Oral Communications 8: Pituitary and Neuroendocrinology | ECE2021

Increased PCSK1N in silent corticotroph pituitary adenomas may explain their “silence”

Ringvoll Normann Kjersti , Kristin Berland Astrid Berland , Olsen Linn Guro , Lekva Tove , Dahlberg Daniel , Bollerslev Jens , Petter Berg Jens , Cristina Olarescu Nicoleta

BackgroundCorticotroph pituitary adenomas present different degrees of functionality, from silent to whispering and finally to functioning adenomas leading to Cushing’s disease. Compared to their functioning (FCA) counterpart, the silent corticotroph adenomas (SCA) express lower levels of the corticotroph cell lineage marker–TBX19 (TPIT), proopiomelanocortin (POMC), and prohormone converting enzyme 1/3 (PC1/3, PCSK1)–t...